On April 28, 2017, the signing ceremony of the ACTL technology project cooperation between Shenzhen Yishi Kangning Biotechnology Co., Ltd. and Singapore World Health Group (REGENE GROUP) was successfully held. Mr. Chai Xiaorong, Chairman of ISKCON, and Mr. Liu Dali, Chairman of World Health Group attended the ceremony and signed the cooperation agreement.
According to the cooperation agreement signed by the two parties this time, ISKCON and Shikang Group will carry out strategic cooperation on the development, clinical research and application of ACTL targeted cellular immune technology. Relying on the scientific research platform of the World Health Group and the National Hospital of Singapore and the existing immune cell technology research and development platform of ISKCON, the two parties will work together to build a world-leading anti-tumor biotherapy industry base in Southeast Asian countries such as Singapore and Malaysia; it will be built in compliance with international standards. It also plans to establish the world’s first biotherapy center focused on cancer treatment, providing first-class anti-tumor immunotherapy and services to cancer patients in East Asia, Southeast Asia and the world, as well as providing technical training, Support and other related services, the total investment will exceed 100 million US dollars.
Singapore's biotechnology is in a leading position in the world, and its medical level ranks among the top five in the world, and patients from all over the world are attracted to it. Shikang Group is a leading brand in the field of cell therapy in Singapore, specializing in the research and development and application of life technology and new drugs. The expert team covers the United States, the United Kingdom, Australia, China, Malaysia, Hong Kong and Singapore. As a leader in the development and application of targeted anti-tumor cell immunotherapy technology in China, Ishikoning has accumulated a deep technical foundation and rich research experience in the field of tumor immunotherapy.
This signing marks the official entry of ACTL technology into the international market and is an important step taken by ISKCON to realize the globalization strategy of ACTL technology. With the help of the establishment of this international partnership, ISKCON has placed itself in a large international environment, participated in the formation of the global immune cell industry pattern and continuously improved its international competitiveness. ISKCON and World Health Group will fully complement each other's advantages globally, effectively integrate anti-tumor immune cell technology and resources, and ensure that the latest technology obtained in the field of immune cell anti-tumor can achieve clinical transformation at the fastest speed.